ESTRO recommendations for the use, planning and delivery of reirradiation in locally recurrent rectal cancer - Endorsed by ASTRO.
Heike M U Peulen, Heidi S Rønde, Camilla Kronborg et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and practice guideline by ESTRO, endorsed by ASTRO, addresses reirradiation in locally recurrent rectal cancer (LRRC). It emphasizes the importance of careful patient selection and treatment planning to optimize outcomes and minimize adverse effects. The recommendations are primarily based on low-quality evidence and expert consensus, highlighting the need for further prospective studies.
Key findings
- Reirradiation doses ≥ 30 Gy have historically raised concerns about significant adverse effects.
- Recommendations were mostly based on low-quality evidence or expert opinion.
- Optimal patient selection and advanced imaging techniques are crucial for maximizing therapeutic benefits.
Why it matters
Understanding the guidelines for reirradiation in LRRC is essential for clinicians to enhance treatment consistency and quality. These recommendations aim to improve patient outcomes while addressing safety concerns associated with reirradiation.
What to keep in mind
Almost all levels of evidence were low, indicating a lack of robust data to support the recommendations.